BOSTON, Massachusetts, USA | November 18, 2026
Pyxis Oncology, Inc. has announced updated Phase 1 clinical data for its investigational cancer therapy micvotabart pelidotin (MICVO), demonstrating encouraging and durable responses in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The updated findings will be presented as a late-breaking oral presentation at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, taking place from November 18–20, 2026, in Barcelona, Spain. The results, based on an October 14, 2026 data cutoff, demonstrated a 39% confirmed objective response rate (cORR), a 94% disease control rate (DCR) and a median duration of response of 9.2 months among 33 efficacy-evaluable patients. These findings provide additional clinical evidence supporting the continued development of MICVO as a potential treatment option for patients whose cancer has progressed following previous therapies.
MICVO Demonstrates Durable Responses in Advanced Cancer
MICVO, also known as micvotabart pelidotin, is an investigational antibody-drug conjugate (ADC) designed to target extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is selectively overexpressed in the tumor microenvironment of several solid cancers. The therapy is designed to deliver its cytotoxic payload to tumor-associated tissue and works through three proposed mechanisms: direct cancer cell killing, bystander effects and immunogenic cell death. This approach aims to improve the delivery of cancer-killing activity within tumors while potentially influencing the surrounding tumor microenvironment.MICVO, also known as micvotabart pelidotin, is an investigational antibody-drug conjugate (ADC) designed to target extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is selectively overexpressed in the tumor microenvironment of several solid cancers. The therapy is designed to deliver its cytotoxic payload to tumor-associated tissue and works through three proposed mechanisms: direct cancer cell killing, bystander effects and immunogenic cell death. This approach aims to improve the delivery of cancer-killing activity within tumors while potentially influencing the surrounding tumor microenvironment.The durability findings were also notable, with a median duration of response of 9.2 months and median progression-free survival of 6.7 months. The estimated probability of overall survival at 12 months was 81%. Additionally, the median progression-free survival observed with MICVO was 6.7 months, compared with 4.2 months on patients’ most recent prior therapy. The company reported clinical activity across different human papillomavirus (HPV) statuses and prior-treatment subgroups, suggesting that the observed activity was not restricted to a single patient subgroup.
Updated Safety Findings Support Further Development
Alongside efficacy results, Pyxis Oncology reported additional safety findings from the ongoing Phase 1 study. The updated analysis showed no new cases of Grade 3 peripheral neuropathy since the previous data update. All six patients who had previously experienced Grade 3 peripheral neuropathy demonstrated improvement, with five patients recovering to Grade 1 or better and one improving to Grade 2.Peripheral neuropathy is a potential treatment-related adverse event involving damage or dysfunction of peripheral nerves and can affect sensation, movement and daily activities. The improvement observed in these patients is an important safety finding as the company continues evaluating MICVO’s tolerability and dose-management strategies. However, these observations should be interpreted within the limitations of an early-stage clinical study and do not establish the long-term safety profile of the investigational treatment.The updated findings will be presented by Faye Johnson, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, during the late-breaking oral clinical trials session on November 19, 2026, at the Barcelona conference. Pyxis Oncology also announced a live webcast scheduled for November 19 to discuss the updated clinical results and development strategy.
Merck Collaboration and Planned Phase 3 Trial
Pyxis Oncology is also advancing MICVO through an existing clinical trial collaboration with Merck & Co., evaluating the investigational ADC in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 immunotherapy. The combination is being investigated in a separate Phase 1/2 clinical study involving patients with recurrent or metastatic HNSCC and other advanced solid tumors. This research explores the potential of combining targeted ADC treatment with immune checkpoint inhibition to improve cancer treatment outcomes. The current announcement specifically reports monotherapy findings and does not represent new collaboration terms or a new agreement with Merck.Based on the updated monotherapy findings, Pyxis Oncology plans to advance MICVO into the global Phase 3 Headliner clinical trial, targeting initiation in mid-2027 for patients with second-line and beyond recurrent or metastatic HNSCC. The company also expects more mature overall survival data during the first half of 2027, alongside further regulatory discussions regarding the planned pivotal development program.The latest findings represent an important clinical development milestone for Pyxis Oncology and highlight continued innovation in antibody-drug conjugates and targeted cancer therapies. While the Phase 1 results are encouraging, further evaluation in larger clinical studies will be necessary to confirm MICVO’s efficacy, safety and potential role in treating advanced head and neck cancer.
Source: Pyxis Oncology ,Merck press release



